p53 Status and Tumor Cell Response to Radioimmunotherapy using 125I-mAbs

Author： Piron B.   Chouin N.   Bardies M.   Pelegrin A.   Pouget J.-P.  

Publisher： Edp Sciences

E-ISSN： 1769-700x|43|5|234-234

ISSN： 0033-8451

Source： Radioprotection, Vol.43, Iss.5, 2008-09, pp. : 234-234

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

p53 Gene Status and Response to Topotecan-Containing Chemotherapy in Advanced Ovarian Carcinoma

By  

Oncology, Vol. 69, Iss. 2, 2005-09 ,pp. : 154-158

Karger

Access to resources Recommend Favorite

Association between Inducible Nitric Oxide Synthase Expression and p53 Status in Human Esophageal Squamous Cell Carcinoma

By  

Oncology, Vol. 64, Iss. 1, 2002-12 ,pp. : 90-96

Karger

Access to resources Recommend Favorite

Loss of Sparc in p53‐null Astrocytes Promotes Macrophage Activation and Phagocytosis Resulting in Decreased Tumor Size and Tumor Cell Survival

By  

BRAIN PATHOLOGY, Vol. 25, Iss. 4, 2015-07 ,pp. : 391-400

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Possible Prognostic Significance of p53 Immunostaining Status of the Primary Tumor in Patients Developing Local Recurrence after Breast-Conserving Surgery

By  

Oncology, Vol. 55, Iss. 5, 1998-08 ,pp. : 450-455

Karger

Access to resources Recommend Favorite

Prognostic Significance of Pretreatment 18F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using 131I-Rituximab

By  

Acta Haematologica, Vol. 130, Iss. 2, 2013-03 ,pp. : 74-82

Karger

Access to resources Recommend Favorite